B+
Bull case
20%
Probability
Target price
$70.00
Analysis reference price unavailable
Analysis 2026-03-27 · RankAlpha Sentiment AI
KOD
Kodiak SciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Positive GLOW2 topline leads to an expedited regulatory path and clear submission timeline; strong uptake expectations in the addressable diabetic retinopathy market and favorable pricing/coverage assumptions drive material upside to the anchor.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Commercial uptake and reimbursement uncertainty
Momentum
100
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $42.00 · Bull $70.00 · Bear $18.00Analysis 2026-03-27; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-27 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $121.67
Why
Momentum100 · Δ7d -0.0
Value41 · Δ7d -0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Commercial uptake and reimbursement uncertainty
- • Insufficient cash runway or dilutive financing
- • Follow-up data or regulatory feedback raises additional evidence requirements, delaying submission and increasing cash-burn/funding risk; broader market re-rating back toward analyst median/low occurs if milestones slip.
Catalyst clock
2026-03-26
Positive topline announced from GLOW2 Phase 3 (market-moving press release / 8-K)
Lead driver: Value · See fundamentals
Momentum
100
8% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+1.0
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
0
45% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 99.9 / Value 40.6 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-03-27. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-03-27 · RankAlpha Sentiment AI
B-
Bear case
30%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-03-27 · RankAlpha Sentiment AI
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$5.51B
Beta
2.65
Shares Out
62.85M
P/E (TTM) · Derived
-20.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-31.83
Rev YoY
-
EPS YoY
+1.8%
Gross Margin
-
Op Margin
-
Net Debt
-$50.68M
Current Ratio
2.49
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data